Saturday, 31 October 2026European Markets

OREGE Stock Bearish By 20% In The Last 10 Sessions

Loading stream...

orege, a reputable french company renowned for its top-notch sludge and effluent treatment solutions, recently reported a significant plunge in its market value. a notable 20.66% depreciation was recorded over ten trading sessions, seeing the share price fall from eur0.67 to a record low of eur0.53. strikingly, this downward trajectory seemed to reflect a similar trend on france's cac 40 index, with orege's shares taking an additional hit and sinking even further to eur0.53. this was a drastic 35% slump from their 52-week high of eur0.82.

orege's operations

based in voisins-le-bretonneux, france, orege serves the municipal and industrial waste treatment sectors. the company's diverse portfolio comprises everything from conditioner solutions to routine maintenance services. orege operates under the umbrella of eren groupe sa, providing robust support in the waste treatment landscape.

the trigger behind orege's market drop

the sudden fall in orege's share value can be attributed to several factors. key among these is the company's dramatic year-on-year revenue surge of 62.1 percent. even though trailing 12-month revenue now peaks at 3.47m, the firm's earnings per share (eps) lamentably remain in the negative at eur-0.12. in addition, orege's shares have been changing hands at significantly low volumes, way below the company's average trading volume. the most recent reported trading volume stood at 34,084, an 81% drop compared to their normal volume of 232,102.

future prospects for orege's shares

considering the above observations, one might be tempted to view orege shares as being undervalued given its remarkable revenue growth despite the negative eps. the stock price volatility of its subsidiary may be a reflection of investor sentiment towards the parent company, eren groupe sa. additionally, the low trading volume could be suggestive of waning investor enthusiasm. when bundled together with declining share prices, the resultant bearish outlook might signal caution. nonetheless, as with any investment in the stock market, due diligence coupled with an understanding of wider market trends remains critical in shaping informed investment choices.

more news about orege (orege.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com